吉田病院TOP > 臨床研究センター > 研究業績

image/svg+xml

論文（英文誌）

2024年度

  1. Real-World Treatment Outcomes in the First and Subsequent Coronavirus Disease 2019 (COVID-19) Hospital Clusters.
    Yoshinobu Ohsaki, Takaaki Sasaki, Yasuhiro Umekage, Hiraku Yanada, Mariko Ishikawa, Ryohei Yoshida
    Cureus.78981 DOI: 10.7759 2025年2月14日
  2. Treatment of lung adenocarcinoma with chemotherapy helps mitigate chronic myeloid leukaemia progression: A case report.
    Nagasue K, Kida R, Shigaki R, Nitanai K, Yagita A, Yanada H, Umekage Y, Mori C, Minami Y, Funayama T, Yamamoto M, Tanino M, Yoshida R, Sasaki T.
    Oncol Lett. 2024 Oct 25;29(1):31. doi: 10.3892/ol.2024.14777. eCollection 2025 Jan.
  3. Viability and diagnostic potential of tissues obtained through cryobiopsy.
    Kida R, Yoshida R, Nitanai K, Yagita A, Naraoka T, Yanada H, Shigaki R, Tenma T, Mori C, Umekage Y, Mitsumoto M, Tanino M, Minami Y, Sasaki T.Respir Investig. 2024 Nov;62(6):1220-1226. doi: 10.1016/j.resinv.2024.10.011. Epub 2024 Nov 5.
  4. Real-World Efficacy of Ensitrelvir in Hospitalized Patients With COVID-19 in Japan: A Retrospective Observational Study.
    Ryohei Yoshida, Takaaki Sasaki, Yoshinobu Ohsaki
    Cureus 16(5) e61048 2024年5月

2023年度

  1. Detection of resistance mutations in patients with anaplastic lymphoma kinase-rearranged lung cancer through liquid biopsy.
    Takaaki Sasaki, Ryohei Yoshida, Kiichi Nitanai, Takashi Watanabe, Toshiyuki Tenma, Ryotaro Kida, Chie Mori, Yasuhiro Umekage, Noriko Hirai, Yoshinori Minami, Shunsuke Okumura
    Translational lung cancer research 12(7) 1445-1453 2023年7月31日
  2. Two Cases of SMARCA4-Deficient Non-small Cell Lung Cancer (NSCLC) with Improved Performance Status (PS) after Treatment with Immune Checkpoint Inhibitors (ICIs)
    Akiko Koizumi, Yukiho Tamura, Ryohei Yoshida, Chie Mori, Yusuke Ono, Mishie Tanino, Yusuke Mizukami, Takaaki Sasaki
    Cureus 2023年4月16日
  3. Case Report: Case series: association between blood concentration and side effects of sotorasib.
    Ryota Shigaki, Ryohei Yoshida, Akari Yagita, Kazunori Nagasue, Taeka Naraoka, Kiichi Nitanai, Hiraku Yanada, Toshiyuki Tenma, Ryotaro Kida, Yasuhiro Umekage, Chie Mori, Yoshinori Minami, Hideki Sato, Kuninori Iwayama, Yasuhisa Hashino, Masahide Fukudo, Takaaki Sasaki
    Frontiers in oncology 13 1269991-1269991 2023年

2022年度

  1. MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer.
    Shunsuke Kitajima, Tetsuo Tani, Benjamin F Springer, Marco Campisi, Tatsuya Osaki, Koji Haratani, Minyue Chen, Erik H Knelson, Navin R Mahadevan, Jessica Ritter, Ryohei Yoshida, Jens Köhler, Atsuko Ogino, Ryu-Suke Nozawa, Shriram K Sundararaman, Tran C Thai, Mizuki Homme, Brandon Piel, Sophie Kivlehan, Bonje N Obua, Connor Purcell, Mamiko Yajima, Thanh U Barbie, Patrick H Lizotte, Pasi A Jänne, Cloud P Paweletz, Prafulla C Gokhale, David A Barbie
    Cancer cell 40(10) 1128-1144 2022年10月10日
  2. MET-induced CD73 restrains STING-mediated immunogenicity of EGFR-mutant lung cancer.
    Ryohei Yoshida, Maria Saigi, Tetsuo Tani, Benjamin F Springer, Hirofumi Shibata, Shunsuke Kitajima, Navin R Mahadevan, Marco Campisi, William Kim, Yoshihisa Kobayashi, Tran C Thai, Koji Haratani, Yurie Yamamoto, Shriram K Sundararaman, Erik H Knelson, Amir Vajdi, Israel Canadas, Ravindra Uppaluri, Cloud P Paweletz, Juan J Miret, Patrick H Lizotte, Prafulla C Gokhale, Pasi A Janne, David A Barbie
    Cancer research 82(21) 4079-4092 2022年9月6日

2021年度

  1. Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
    Ryo Ariyasu, Ken Uchibori, Takaaki Sasaki, Mika Tsukahara, Kazuma Kiyotani, Ryohei Yoshida, Yusuke Ono, Satoru Kitazono, Hironori Ninomiya, Yuichi Ishikawa, Yusuke Mizukami, Noriko Yanagitani, Naoya Fujita, Makoto Nishio, Ryohei Katayama
    Cancer science 112(6) 2371-2380 2021年6月
  2. The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer.
    Satoshi Okazaki, Takaaki Sasaki, Shunsuke Yasuda, Masahiro Abe, Nana Yoshida, Ryohei Yoshida, Kei Ishibashi, Yoshinori Minami, Shunsuke Okumura, Shinichi Chiba, Hidehiro Takei, Ryusuke Hayashi, Toshihiro Nagato, Hiroya Kobayashi, Ayumu Sugitani, Yusuke Ono, Yusuke Mizukami, Masahiro Kitada, Yoshinobu Ohsaki
    Oncology letters 21(5) 420-420 2021年5月

2020年度

  1. EGFR blockade activates interferon
    Ryohei Yoshida, David A. Barbie
    NATURE CANCER 1(4) 376-378 2020年4月
  2. Tumor-Derived cGAMP Regulates Activation of the Vasculature.
    Marco Campisi, Shriram K Sundararaman, Sarah E Shelton, Erik H Knelson, Navin R Mahadevan, Ryohei Yoshida, Tetsuo Tani, Elena Ivanova, Israel Cañadas, Tatsuya Osaki, Sharon Wei Ling Lee, Tran Thai, Saemi Han, Brandon P Piel, Sean Gilhooley, Cloud P Paweletz, Valeria Chiono, Roger D Kamm, Shunsuke Kitajima, David A Barbie
    Frontiers in immunology 11 2090-2090 2020年

2019年度

  1. Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer.
    Jun Sakakibara-Konishi, Hidenori Kitai, Yasuyuki Ikezawa, Yutaka Hatanaka, Takaaki Sasaki, Ryohei Yoshida, Shinichi Chiba, Shingo Matsumoto, Koichi Goto, Hidenori Mizugaki, Naofumi Shinagawa
    Clinical lung cancer 20(5) e555-e559 2019年9月
  2. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.
    Shunsuke Kitajima, Elena Ivanova, Sujuan Guo, Ryohei Yoshida, Marco Campisi, Shriram K Sundararaman, Shoichiro Tange, Yoichiro Mitsuishi, Tran C Thai, Sayuri Masuda, Brandon P Piel, Lynette M Sholl, Paul T Kirschmeier, Cloud P Paweletz, Hideo Watanabe, Mamiko Yajima, David A Barbie
    Cancer discovery 9(1) 34-45 2019年1月

2018年度

  1. Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR.
    Ryohei Yoshida, Takaaki Sasaki, Yasuhiro Umekage, Sachie Tanno, Yusuke Ono, Munehiko Ogata, Shinichi Chiba, Yusuke Mizukami, Yoshinobu Ohsaki
    BMC cancer 18(1) 1136-1136 2018年11月19日
  2. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.
    Yoshitsugu Narumi, Ryohei Yoshida, Yoshinori Minami, Yasushi Yamamoto, Shiori Takeguchi, Kohei Kano, Kae Takahashi, Tsukasa Saito, Jun Sawada, Hiroya Terui, Takayuki Katayama, Takaaki Sasaki, Yoshinobu Ohsaki
    BMC cancer 18(1) 95-95 2018年1月24日

2017年度

  1. "Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer.
    Ryohei Yoshida, Takaaki Sasaki, Yoshinori Minami, Yukiko Hibino, Shunsuke Okumura, Masatoshi Sado, Naoyuki Miyokawa, Satoshi Hayashi, Masahiro Kitada, Yoshinobu Ohsaki
    International journal of oncology 51(5) 1533-1540 2017年11月
  2. EGFR and KRAS Mutations in Triple-Mutated Lung Cancer.
    Ryohei Yoshida, Takaaki Sasaki, Yoshinobu Ohsaki
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 12(7) e92-e93 2017年7月"

Page Top